EN
EN
This project aims to use cutting-edge directed cell differentiation technology to culture and differentiate diabetes-specific stem cells (code ZJ-K-0209) in vitro, fundamentally addressing the β-cell functional problem in patients with type 2 diabetes and achieving long-term, autonomous physiological blood glucose regulation. As a cell innovative drug targeting islet β-cell repair and microenvironment remodeling, it represents the most cutting-edge breakthrough in the fields of regenerative medicine and metabolic diseases today; compared with conventional insulin injection, its goal is to achieve a "functional cure" of diabetes.
Core underlying technology: The project team's globally pioneered chemically induced umbilical cord mesenchymal stem cell technology requires only a specific combination of small-molecule chemical drugs to induce umbilical cord mesenchymal stem cells to differentiate into a specific subtype state, that is, to direct these umbilical cord mesenchymal stem cells in vitro into diabetes-specific stem cells. These cells enhance β-cell number and function and extend β-cell targeting and recirculation time, effectively solving the technical pain point that ordinary stem cells alone can easily cause severe hypoglycemia. The efficacy of diabetes-specific stem cells lies in "immune regulation" and "microenvironment repair," mainly playing anti-inflammatory and microenvironment-improving roles.
Intravenous infusion transplantation: Abandoning traditional hepatic portal vein transplantation, which carries high bleeding risk and easy cell loss, the project team pioneered an "intravenous injection" strategy; this site is superficial, minimally invasive, and provides an excellent vascularized survival microenvironment for transplanted cells.
Zhongjia Biotech (Shenzhen Zhongjia Biotech Medical Technology Co., Ltd.)'s core strategic pipeline is not directly aimed at diabetes; rather, it focuses on developing the underlying technology platform for related cells. Within Zhongjia Biotech there is a fully independent team dedicated to "research and development of cell innovative drugs for the treatment of type 2 diabetes." For exploratory clinical research involving endocrine or diabetes-related conditions (such as various metabolic complications), the team adopts a combined model of "cell preparation platform experts + endocrinology clinical PIs (principal investigators) from top tertiary hospitals."
Zhongjia's core leaders and scientific brains
Qu Shoukang (founder/chairman): As the leader of Zhongjia Biotech, Mr. Qu Shoukang has driven the company's national strategic layout. He strongly promotes the "medical-enterprise cooperation" model and actively advances stem cell clinical research filings for Zhongjia's underlying cell technologies with leading domestic clinical institutions (such as the Union Hospital of Tongji Medical College, Huazhong University of Science and Technology) across multiple disciplines (including endocrinology and critical care medicine).
Professor Lian Qizhou (chief scientist): Professor Lian Qizhou is a top scholar in the field of stem cells and regenerative medicine in China (recipient of a 2023 national-level major talent project and a 2023 Pengcheng Peacock Plan (Category A) specially appointed position), with exceptionally deep academic achievements in stem cell fate regulation, tissue repair, and intervention in metabolic diseases. As Zhongjia's chief scientist, he provides the most core top-level academic guidance for the immune regulation mechanisms and multilineage differentiation potential assessment of the company's various stem cell products.
Dr. Liu Jia and the cell underlying process R&D team: Under the guidance of the chief scientist, Zhongjia has a strong internal team for developing underlying processes (CMC). Led by key members such as Dr. Liu Jia, the team has tackled the "bottleneck" processes of serum-free large-scale expansion, isolation, and purification of difficult cells such as HSC, NSC, iPS, and HFSC. It is this internal quality control and preparation team that ensures the cell preparations delivered to hospitals for various metabolic/immune exploratory studies have extremely high batch consistency and biological safety.
The "medical-enterprise joint model" for diabetes clinical exploration
When Zhongjia's underlying cell platform technology is applied to clinical exploration of diabetes and its complications (such as diabetic foot and diabetic peripheral neuropathy), its "project team" extends outward:
Underlying cell supply side (Zhongjia R&D team): Responsible for stably delivering highly active stem cell preparations in accordance with the standards of the National Medical Products Administration (NMPA) and the National Institutes for Food and Drug Control, and providing cell-level safety/mechanism data support.
Clinical protocol design and execution side (partner hospital endocrinology team): Zhongjia Biotech usually jointly applies for national stem cell clinical research filing projects with large tertiary hospitals. At this stage, the chief physician/professor of the hospital's endocrinology department serves as the project's true "clinical team leader (PI)," fully leading the systematic evaluation of patient enrollment screening, intervention dose and frequency design, and efficacy endpoints (such as changes in glycated hemoglobin and insulin dosage).
At present, global progress in this field is transitioning from early clinical proof of concept to pivotal clinical trials, with differing progress across technology routes. This project is currently in the clinical trial (IIT) advancement stage and is being conducted across multiple centers (Shenzhen Second People's Hospital and Shenzhen Third People's Hospital); Shenzhen Third People's Hospital has filed for stem cell clinical research, and partial clinical data show that multiple patients with type 2 diabetes who received full-dose treatment successfully achieved a "functional cure," completely eliminating exogenous insulin injections, with glycated hemoglobin (HbA1c) returning to normal and no severe hypoglycemic events. The safety, tolerability, and preliminary efficacy of diabetes-specific stem cells in humans are currently being evaluated.
Process iteration and efficiency improvement stage (ongoing): In recent years, the R&D team has continuously optimized the underlying process, greatly shortening the preparation time of diabetes-specific stem cells from about 7 days in the early stage to less than 4 days, laying the foundation for future large-scale industrial production and ensuring that diabetes-specific stem cells can be stably produced at industrial scale for specific cell types.
Regulatory bellwether: In 2023, the U.S. FDA approved Lantidra, the first cell therapy made from pancreatic cells of deceased donors (for the treatment of type 1 diabetes with recurrent severe hypoglycemia), which completely opened the regulatory and approval pathway for subsequent cell innovative drugs.
Zhongjia Biotech's patent moat in underlying technologies is extremely deep. It has filed 6 invention patents and has 4 papers under review awaiting publication, covering the complete industrial chain from underlying cell sources to terminal administration. The core patent pool is mainly concentrated in the following dimensions:
Directed differentiation process patents: This is the most core "know-how." It covers the small-molecule chemical drug formulations, cytokine combinations, and standard operating procedures for culture timing used to direct umbilical cord mesenchymal stem cells to differentiate into specific subtype mesenchymal stem cells.
Directed differentiation medium process: The company holds core methodology patents for the high-purity directed differentiation of umbilical cord mesenchymal stem cells into specific subtype stem cells in a fully defined, serum-free, animal-derived-component-free chemically defined culture system.
Large-scale cell culture and formulation patents: The company has broken through the capacity bottleneck of adherent culture and holds patented processes for large-scale stem cell culture, ensuring stemness maintenance and high batch-to-batch consistency during expansion at the hundred-liter to thousand-liter scale; this is the core barrier for developing a low-cost "off-the-shelf" product.
Stem cell preparation and underlying consumables process patents: Zhongjia also holds technical patents for key underlying materials such as "clinical stem cell-specific cryopreservation solution." This special formulation for cell cryopreservation greatly reduces ice-crystal damage to cells and improves cell recovery viability, building a barrier on the preparation side.
Clinical application technology system and procedures: The team at Shenzhen Second People's Hospital has deep experience and intellectual property protection in clinical application standard systems such as the "3+3" dose design, infusion cycles, and combination drug regimens; the relevant scientific research results are transformed and promoted through Zhongjia Biotech's platform.
This technology is on the eve of an explosion; the maturity of its "functional repair" and the reliability of its "microenvironment remodeling" have been preliminarily confirmed, and safety and efficacy are supported by a large amount of data.
Very high reliability of efficacy (physiological-level glycemic control): From a technical principle perspective, diabetes-specific stem cells have advantages unmatched by conventional artificial insulin pumps. These cells can sense minute changes in glucose concentration in the body in real time and secrete insulin, C-peptide, and amylin on demand with physiological-level precision. Clinical data show that once diabetes-specific stem cells successfully engraft and survive, patients can not only eliminate insulin injections but also eliminate life-threatening severe hypoglycemic events, and the risk of microvascular complications in target organs (kidneys and fundus) is significantly reduced.
Maturity of the directed differentiation process (extremely high): Zhongjia Biotech is at the global top level in the efficiency of complex directed cell differentiation in vitro, off-target rate control, and screening technology. Using umbilical cord mesenchymal stem cells as the chassis cells enables validation of extremely high genomic stability at the single-clone level, fundamentally guaranteeing batch-to-batch consistency and large-scale mass production capability of the final product.
Extremely high cell purity and uniformity (mature and reliable): Unlike the mechanism by which conventional umbilical cord mesenchymal stem cells blindly secrete factors, the greatest advantage of diabetes-specific stem cells lies in "customization with a defined direction." Zhongjia Biotech's directed differentiation process can control the purity of specific cell types at an extremely high level; combined with strict flow sorting, it greatly reduces the risk associated with residual cells.
Safety and reliability (preliminarily validated): Subtype cells derived from umbilical cord mesenchymal stem cells inherently lack a mechanism that triggers graft-versus-host disease and do not cause extremely severe cytokine release syndrome (CRS) and neurotoxicity like CAR-T; early clinical data have shown excellent safety.
Extremely high biological safety (eliminating tumorigenic risks): Conventional gene cell technologies carry the risk of altering the cell genome due to the use of exogenous genes (such as oncogenes), which may cause tumors—this is the biggest "fatal weakness" of stem cell drugs. In contrast, diabetes-specific stem cell technology relies on the transient regulation of small-molecule chemical drugs and does not alter the underlying DNA sequence, greatly reducing the risk of gene mutation and tumorigenesis at the source, achieving a qualitative leap in technical reliability.
Extremely high raw material safety validation (high reliability): Diabetes-specific stem cells are sourced from discarded umbilical cords, with no ethical controversy and extremely low immunogenicity. Zhongjia Biotech's deep accumulation in cell quality control gives this therapy definite reliability in terms of biological safety.
The cell innovative drug targeting islet β-cell repair and microenvironment remodeling represents the core pathway for diabetes treatment to leap from "lifelong exogenous control" to "clinical functional cure." This pipeline not only focuses on direct supplementation or regeneration of β-cell number but also emphasizes breaking the vicious cycle of "hyperglycemia-inflammation-β-cell apoptosis" by regulating local immunity, vascularization, and the stromal microenvironment. The future market demand and prospects of this class of innovative drugs can be analyzed in depth from the following four core dimensions:
Market demand: "cure-level" rigid demand at the limit of conventional therapies
As one of the chronic diseases with the largest patient base worldwide, diabetes is currently treated with conventional therapies (such as exogenous insulin, GLP-1 receptor agonists, and dual receptor agonists) that can control blood glucose but struggle to reverse the pathological process of endogenous islet function failure.
The "unloading" demand of type 2 diabetes (T2D): Patients with mid-to-late-stage T2D face severe insulin resistance and β-cell "dedifferentiation" (loss of secretory function). Remodeling the microenvironment (for example, through mesenchymal stem cells (MSC) or secreted exosomes to reduce local oxidative stress and inflammation) can restore the function of "dormant" or dedifferentiated β-cells and prevent progression to complications.
Ending donor shortage and immune rejection: Although conventional islet transplantation can cure diabetes, donors are extremely scarce and patients require lifelong immunosuppressants. This innovative drug pipeline (often combining human pluripotent stem cell iPSC differentiation with low-immunogenicity modification technologies) was born precisely to address this pain point.
Competitive landscape and technology routes: a technology watershed with many contenders
At present, R&D in this field globally and in China is in an explosive phase, mainly divided into two complementary technology routes:
Technology route | Core mechanism | Representative progress/benchmark |
Exogenous cell replacement + microenvironment remodeling | Use iPSC or hESC to differentiate into mature islet-like cells or β-cells, combined with microencapsulation, biological scaffolds, or low-immunogenicity (HIP) gene editing. | Internationally, Sana Biotechnology (UP421) has achieved stable survival in patients for 14 months without immunosuppressants; domestic clinical research on regenerated islet transplantation has also repeatedly achieved breakthroughs. |
Endogenous targeted repair + microenvironment awakening | Through targeted small molecules, nucleic acid drugs, or functional mesenchymal stem cells (MSC), directly activate pancreatic ductal progenitor cell differentiation, or improve local blood flow and inflammation by secreting factors. | Multiple clinical pipelines using umbilical cord/placenta-derived MSC to remodel the islet microenvironment and protect residual β-cells are in early or mid-to-late stages. |
Prospects for domestic substitution: Diabetes has a high incidence in China and imposes enormous pressure on medical insurance cost control. Compared with international gene-edited cell therapies that cost millions, if domestic pharmaceutical companies can break through localized CMC (chemistry, manufacturing, and controls) and use cost-effective microenvironment remodeling technologies (such as local delivery systems or composite scaffolds) to achieve glycemic control, they will have enormous local competitive advantages.
Commercialization pain points and future breakthrough paths
To bring such cell innovative drugs to mature markets, three core industry barriers must be overcome:
Durability of microenvironment remodeling: the contest between "immune escape" and "vascularization." Pain point: After transplantation, β-cells often undergo hypoxic apoptosis due to the lack of an early capillary network or are attacked by host T cells. Breakthrough path: Next-generation drugs cannot be merely "a single cell" but must be an "integrated system" (for example, co-culture of endothelial cells and β-cells, or the introduction of matrix materials that promote angiogenesis). Whoever can first solve "long-term survival without systemic immunosuppressants (stable maintenance of VCN and expression)" will dominate the market.
The industrialization ceiling of process and quality control (CMC). Pain point: Islet β-cell differentiation involves many steps; ensuring cell maturity in mass production, sensitivity of response to glucose stimulation (GSIS indicators), and avoiding the tumorigenic risk of undifferentiated cells constitutes an extremely high industrial barrier. Breakthrough path: Automated, closed-system reactor expansion processes, together with online spectral monitoring and machine learning (ML)-guided cell sorting, will be key to reducing batch-to-batch variation (RSD) and production costs.
Clinical benefits and economic evaluation. Pain point: Cell therapies are inevitably expensive in the early stage and must demonstrate that their "one-time/long-acting treatment" economic value is superior to "daily medication + complication monitoring." Breakthrough path: Prioritize entry into brittle diabetes patients with drastic blood glucose fluctuations and recurrent severe hypoglycemia, or high-risk populations with early trends toward nephropathy. Proving through clinical data that the therapy can significantly reverse complications and reduce overall hospitalization rates will open the door to commercial insurance and innovative payment.
Summary of future market prospects
Strategic judgment: The cell innovative drug targeting islet β-cell repair and microenvironment remodeling is not an "improver" of conventional glucose-lowering drugs but their "terminator." The market ceiling is extremely high: with global aging and rising incidence of metabolic diseases, this therapy faces a multi-billion-dollar, ultra-large market with a cure premium. Policy dividend period: Whether in China or globally, source-level intervention for major chronic diseases and cell regenerative medicine are in policy green channels. Underlying evolution logic: The future core competitiveness of the product will depend on "cell functional maturity," "local immune privilege capability," and "affordability of manufacturing cost." Whichever product can first clinically demonstrate data showing independence from immunosuppressants, long-term stable secretion of C-peptide (characterizing endogenous insulin levels), and effective local microenvironment remodeling will directly secure the industry high ground of future diabetes therapy.









